Recent Updates
Recently added Catalysts
ETRA Positive Sentiment

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

Wednesday, October 22, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Electra Therapeutics announced a $183 million Series C financing to support its lead candidate ELA026 in a pivotal trial for secondary hemophagocytic lymphohistiocytosis. The funding will also facilitate the expansion of ELA026 into hematologic cancers and advance the second pipeline program, ELA822.

Market Sentiment Analysis

POSITIVE FACTORS

  • Secured $183 million in Series C financing.
  • Funding supports pivotal trial for ELA026.
  • Expansion into hematologic cancers planned.
  • Advancement of ELA822 into clinical development.

Full Press Release Details

Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in hematologic cancers and advance second pipeline program, ELA822, into the

Frequently Asked Questions

What is the purpose of the $183 million financing?

The financing will fund a pivotal trial for ELA026 and support its expansion.

What is ELA026 used for?

ELA026 is a treatment for secondary hemophagocytic lymphohistiocytosis.

What other programs will the financing support?

It will advance the second pipeline program, ELA822, into clinical development.

What type of cancers is ELA026 expanding into?

ELA026 will expand into hematologic cancers.

ShareAdd on Google
Tags: ETRA Electra Therapeutics ELA026 Series C sHLH hematic cancers
Last updated: Oct 22, 2025